Description

2-[[(5S)-2-Oxo-3-[2,3,5,6-Tetradeuterio-4-(3-Oxomorpholin-4-Yl)Phenyl]-1,3-Oxazolidin-5-Yl]Methyl]Isoindole-1,3-Dione is a deuterated derivative of a key pharmaceutical intermediate, offering enhanced metabolic stability for advanced research and development. This compound is specifically designed for use in the synthesis of deuterated drug candidates, where the incorporation of deuterium can significantly improve pharmacokinetic profiles. It is an essential building block for medicinal chemists and pharmaceutical companies engaged in the development of novel therapeutics, particularly in areas requiring precise isotopic labeling.

Application

• Deuterated Active Pharmaceutical Ingredient (API) Synthesis: A critical intermediate in the production of deuterium-labeled pharmaceuticals for improved drug efficacy and safety.
• Isotope-Labeled Reference Standard: Used as a certified reference material (CRM) for quantitative analysis (e.g., LC-MS/MS) in bioanalytical and pharmacokinetic studies.
• Metabolic Stability Research: Employed in preclinical research to study the effect of deuterium substitution on the metabolic pathways and half-life of drug candidates.
• Proteomics and Biomarker Discovery: Serves as a stable isotope-labeled internal standard for accurate mass spectrometry-based quantification in complex biological matrices.
• Process Chemistry & Scale-Up: Used in the development and optimization of scalable synthetic routes for deuterated compounds under cGMP conditions.
• Academic & Contract Research: A valuable reagent for universities and CROs conducting cutting-edge research in medicinal chemistry and isotope chemistry.

Basic Information

Product Name	2-[[(5S)-2-Oxo-3-[2,3,5,6-Tetradeuterio-4-(3-Oxomorpholin-4-Yl)Phenyl]-1,3-Oxazolidin-5-Yl]Methyl]Isoindole-1,3-Dione
CAS No.	1330180-09-0
Molecular Formula	C22H16D4N3O5
Molecular Weight	412.42 g/mol
Synonyms	(5S)-5-[(1,3-Dioxo-2,3-dihydro-1H-isoindol-2-yl)methyl]-3-[4-(2,6-dioxomorpholin-4-yl)-2,3,5,6-tetradeuteriophenyl]oxazolidin-2-one; Deuterated Rivaroxaban Intermediate; 2,3,5,6-Tetradeuterio-4-(3-oxomorpholin-4-yl)phenyl Oxazolidinone Derivative; (5S)-5-[(Phthalimido)methyl]-3-[4-(3-oxomorpholino)-2,3,5,6-tetradeuteriophenyl]-2-oxazolidinone; Tetradeuterated Rivaroxaban Related Compound; [D4]-Labeled Oxazolidinone Isoindole-1,3-dione; Rivaroxaban-d4 Precursor; N-[[(5S)-2-Oxo-3-[4-(2,6-dioxo-4-morpholinyl)-2,3,5,6-tetradeuteriophenyl]-5-oxazolidinyl]methyl]-1,2-benzenedicarboximide
EINECS	Contact for details

Quality Control

Our deuterated compounds are manufactured under strict quality systems to ensure high isotopic purity and chemical integrity. Each batch is characterized by advanced analytical techniques including NMR (1H, 13C, 2H), HPLC, and Mass Spectrometry. A comprehensive Certificate of Analysis (COA) is provided, detailing chemical purity, isotopic enrichment (D-content), and impurity profiles. We support development and commercial projects with materials suitable for research use and can supply under cGMP standards for advanced clinical applications upon request.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature (15-25°C) in a dry environment. This compound is moisture-sensitive; keep the container tightly sealed under an inert atmosphere (e.g., nitrogen or argon) when not in use to maintain stability and isotopic integrity.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (IR)	Conforms to structure
Identification (NMR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Isotopic Purity (Deuterium Content)	≥ 98 atom % D
Loss on Drying	≤ 0.5%
Residue on Ignition	≤ 0.1%
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.